Showing results (41-50 of 88) with videos related to
Sort By:
Pageof 9
Expert Opinion on Pharmacotherapy|October 30, 2015
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenibAndrea Casadei Gardini, Giorgia Marisi, Emanuela Scarpi, et al.Journal for Immunotherapy of Cancer|April 21, 2023
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE studyRoberto Moretto, Daniele Rossini, Aurélie Catteau, et al.JCO Precision Oncology|April 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal CancerRoberto Moretto, Marco Maria Germani, Martina Carullo, et al.Oncotarget|April 9, 2016
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS studyAndrea Casadei Gardini, Giorgia Marisi, Luca Faloppi, et al.BMC Cancer|July 24, 2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancerCarlotta Antoniotti, Beatrice Borelli, Daniele Rossini, et al.European Journal of Cancer (Oxford, England : 1990)|October 25, 2025
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trialEleonora Cristarella, Margherita Ambrosini, Massimo Di Maio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2024
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES StudyCarmine Pinto, Armando Orlandi, Nicola Normanno, et al.European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.BMC Cancer|April 8, 2025
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trialVincenzo Nasca, Francesca Bergamo, Luisa Foltran, et al.The Oncologist|January 17, 2020
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup AnalysisGerardo Rosati, Fabio Galli, Maurizio Cantore, et al.Pageof 9